beta
IA Trial Radar
El ensayo clínico NCT04747314 (TNA-LBP) para Dolor lumbar crónico, Negative Affectivity está activo, no reclutando. Consulte la vista de tarjeta del Radar de Ensayos Clínicos y las herramientas de descubrimiento de IA para conocer todos los detalles. O haga cualquier pregunta aquí.
Un ensayo coincide con los criterios de filtro
Vista de tarjeta
Volver a la búsqueda

Treating Negative Affect in Low Back Pain Patients (TNA-LBP)

Activo, no reclutando
Los detalles del ensayo clínico están disponibles principalmente en inglés. ¡Sin embargo, IA Trial Radar puede ayudar! Simplemente haga clic en 'Explicar el ensayo' para ver y discutir la información del ensayo en el idioma que haya seleccionado.
El ensayo clínico NCT04747314 (TNA-LBP) está diseñado para estudiar el tratamiento de Dolor lumbar crónico, Negative Affectivity. Es un estudio intervencionista de Fase II Fase III. Su estado actual es: activo, no reclutando. El ensayo se inició el 31 de marzo de 2021, con el objetivo de reclutar a 330 participantes. Dirigido por Ajay Wasan, MD, Msc, se espera que finalice el 30 de abril de 2026. Los datos se actualizaron por última vez en ClinicalTrials.gov el 13 de marzo de 2025.
Resumen
This study will examine how the use of antidepressant, physical therapy, and combination of both affects pain, function, and depression outcomes in chronic low back pain patients.
Descripción detallada
Approximately 20 million Americans are affected by chronic low back pain and negative affective states such as depression and anxiety. These negative states have all been associated with higher pain intensity, lower pain tolerance, greater use of pain medication, poor pain treatment responses, and higher levels of psychiatric comorbidity among low back pain patients. To improve these outcomes for those who suffer from low back pain, it is important to implement multiple methods with a focus in treating negative affect for pain management rather than using opioids alone.

Antidepressant (AD) and fear avoidance-based physical therapy (EFAR) have individually shown to be promising methods for pain management. In this study, AD, EFAR, and the combination therapy of the two treatments will be explored and implemented to investigate their effectiveness in improving pain, function, depression, and anxiety. The key innovation is testing a new and effective multimodal treatment that can help manage pain, as well as address negative affect.

Título oficial

Proof of Concept Study to Treat Negative Affect in Chronic Low Back Pain

Condiciones médicas
Dolor lumbar crónicoNegative Affectivity
Publicaciones
Artículos científicos y trabajos de investigación publicados sobre este ensayo clínico:
Otros ID del ensayo
Número del NCT
NCT04747314
Inicio del ensayo (real)
2021-03-31
Última actualización
2025-03-13
Fecha de finalización (estimada)
2026-04-30
Inscripción (prevista)
330
Tipo de estudio
Intervencionista
FASE
Fase II
Fase III
Estado general
Activo, no reclutando
Palabras clave
chronic pain
low back pain
fibromyalgia
mood
affect
depression
anxiety
opioid use
Objetivo principal
Tratamiento
Método de asignación
Aleatorizado
Modelo de intervención
Asignación secuencial
Enmascaramiento
Doble ciego
Brazos / Intervenciones
Grupo de participantesIntervención/Tratamiento
ExperimentalAntidepressant (AD)
Subjects will be randomly assigned to receive the antidepressant medication for 4 months under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks. Non-responders determined at the end of 4 months will be re-randomized to continue receiving AD or EFAR for another 4 months.
Antidepressant
The antidepressant treatment utilizes antidepressant medication to improve pain, function, and depression outcomes. The Antidepressant Treatment History Form (ATHF) will be used to assess adequacy of any prior antidepressant medication treatment and to assist the decision regarding which antidepressant to start. A medication flowchart will help serve as a guideline throughout the drug selection and dosing determination. Weekly assessments completed by subjects will help determine response, tolerability, and necessity for dose adjustment or medication change.
ExperimentalEnhanced Fear Avoidance Rehabilitation (EFAR)
Subjects will be randomly assigned to receive 8 1-hour physical therapy sessions, pain education, and motivational messaging via Vivify app for 4 months, in addition to their current opioid prescription and weaning guidelines, if applicable. Trained physical/occupational therapists will determine the activities as part of the treatment. Non-responders determined at the end of 4 months will be re-randomized to continue receiving EFAR or AD for another 4 months.
Enhanced Fear Avoidance Rehabilitation
The EFAR treatment utilizes physical therapy, pain education, and motivational messaging to improve pain, function, and depression outcomes. Subjects will engage in gradual exposure to exercises and activities they are apprehensive about, such as standing to wash dishes.
ExperimentalAntidepressant (AD) + Enhanced Fear Avoidance Rehabilitation (EFAR)
Subjects will receive a combination of antidepressant medication and physical therapy for 8 months, in addition to their current opioid prescription and weaning guidelines, if applicable. No re-randomization will be done in this treatment group.
Antidepressant
The antidepressant treatment utilizes antidepressant medication to improve pain, function, and depression outcomes. The Antidepressant Treatment History Form (ATHF) will be used to assess adequacy of any prior antidepressant medication treatment and to assist the decision regarding which antidepressant to start. A medication flowchart will help serve as a guideline throughout the drug selection and dosing determination. Weekly assessments completed by subjects will help determine response, tolerability, and necessity for dose adjustment or medication change.
Enhanced Fear Avoidance Rehabilitation
The EFAR treatment utilizes physical therapy, pain education, and motivational messaging to improve pain, function, and depression outcomes. Subjects will engage in gradual exposure to exercises and activities they are apprehensive about, such as standing to wash dishes.
ExperimentalAD -> EFAR
Subjects will be randomly assigned to receive the antidepressant medication for 4 months under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks. Non-responders determined at the end of 4 months will be re-randomized to continue receiving AD or EFAR for another 4 months. Those re-randomized to receive EFAR for another 4 months will receive a combination of antidepressant medication and physical therapy, in addition to their current opioid prescription and weaning guidelines, if applicable.
Antidepressant
The antidepressant treatment utilizes antidepressant medication to improve pain, function, and depression outcomes. The Antidepressant Treatment History Form (ATHF) will be used to assess adequacy of any prior antidepressant medication treatment and to assist the decision regarding which antidepressant to start. A medication flowchart will help serve as a guideline throughout the drug selection and dosing determination. Weekly assessments completed by subjects will help determine response, tolerability, and necessity for dose adjustment or medication change.
Enhanced Fear Avoidance Rehabilitation
The EFAR treatment utilizes physical therapy, pain education, and motivational messaging to improve pain, function, and depression outcomes. Subjects will engage in gradual exposure to exercises and activities they are apprehensive about, such as standing to wash dishes.
ExperimentalEFAR -> AD
Subjects will be randomly assigned to receive 8 1-hour physical therapy sessions, pain education, and motivational messaging via Vivify app for 4 months, in addition to their current opioid prescription and weaning guidelines, if applicable. Trained physical/occupational therapists will determine the activities as part of the treatment. Non-responders determined at the end of 4 months will be re-randomized to continue receiving EFAR or AD for another 4 months. Those re-randomized to receive AD for another 4 months will be under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks.
Antidepressant
The antidepressant treatment utilizes antidepressant medication to improve pain, function, and depression outcomes. The Antidepressant Treatment History Form (ATHF) will be used to assess adequacy of any prior antidepressant medication treatment and to assist the decision regarding which antidepressant to start. A medication flowchart will help serve as a guideline throughout the drug selection and dosing determination. Weekly assessments completed by subjects will help determine response, tolerability, and necessity for dose adjustment or medication change.
Enhanced Fear Avoidance Rehabilitation
The EFAR treatment utilizes physical therapy, pain education, and motivational messaging to improve pain, function, and depression outcomes. Subjects will engage in gradual exposure to exercises and activities they are apprehensive about, such as standing to wash dishes.
Resultado primario
Medida de resultadoDescripción de la medidaPeriodo de tiempo
Change from Baseline Physical Function at 4 months using PROMIS (combined with pain intensity to form a combined measure)
The PROMIS Short Form v2.0 - Physical Function 6b questionnaire will assess self-reported capability with 6 qualitatively scaled questions ranked on a 5-point scale, from "without any difficulty" to "unable to do" or "not at all" to "cannot do." The minimum raw summed score is 6 and the maximum score is 30. Lower t-scores suggest better outcomes.
Baseline vs. 4 months
Change from Baseline Pain Intensity at 4 months using PROMIS (combined with function to form a combined measure).
The PROMIS Numeric Rating Scale v1.0 - Pain Intensity 1a questionnaire will assess how much a person hurts with a question ranked on a 11-point scale, from "0 = no pain" to "10 = worst imaginable pain." The minimum raw summed score is 0 and the maximum score is 10. Lower raw response scores suggest lower pain intensity and better outcomes.
Baseline vs. 4 months
Change from Baseline Depression at 4 months using PROMIS
The PROMIS Short Form v1.0 - Depression 4a will assess self-reported negative mood and views of self with 4 questions ranked on a 5-point scale, from "never" to "always". The minimum raw summed score is 4 and the maximum score is 20. Lower t-scores suggest better outcomes. Outcomes will be measured and compared between the 3 treatment groups.
Baseline vs. 4 months
Resultado secundario
Medida de resultadoDescripción de la medidaPeriodo de tiempo
Change from Baseline Pain Interference at 4 months using PROMIS
The PROMIS Short Form v1.1 - Pain Interference 4a will assess self-reported consequences of pain with 4 questions ranked on a 5-point scale, from "not at all" to "very much". The minimum raw summed score is 4 and the maximum score is 20. Lower t-scores suggest better outcomes. Outcomes will be measured and compared between the 3 treatment groups.
Baseline vs. 4 months
Change from Baseline Anxiety at 4 months using PROMIS
The PROMIS Short Form v1.0 - Anxiety 4a will assess self-reported fear, anxious misery, hyperarousal, and somatic symptoms with 4 questions ranked on a 5-point scale, from "never" to "always". The minimum raw summed score is 4 and the maximum score is 20. Lower t-scores suggest better outcomes. Outcomes will be measured and compared between the 3 treatment groups.
Baseline vs. 4 months
Change from Baseline Sleep at 4 months using PROMIS
The PROMIS Short Form v1.0 - Sleep Disturbance 6a self-reported perceptions of sleep quality and sleep depth with 6 questions ranked on a 5-point scale. The minimum raw summed score is 6 and the maximum score is 30. Lower t-scores suggest better outcomes. Outcomes will be measured and compared between the 3 treatment groups.
Baseline vs. 4 months
Change from Baseline Opioid Cravings at 4 months using the Craving Index
The Craving Index questionnaire will assess opioid cravings with 4 questions ranked on a 0-10 scale, from "0 = not at all" to the "10 = strong as possible." Lower scores suggest lower craving.
Baseline vs. 4 months
Change from Baseline Subject's Perception of Change from Treatment at 4 months using Patient Global Impression of Change (PGIC)
The subject's impression of the impact of the treatment on their pain and function will be measured with a 7-item scale (1 = very much worse, 2 = much worse, 3 = minimally worse, 4 = no change, 5 = minimally improved, 6 = much improved, 7 = very much improved).
Baseline vs. 4 months
Change from Baseline Opioid Misuse at 4 months using Current Opioid Misuse Measure
The Current Opioid Misuse Measure (COMM) questionnaire will assess recent feelings and behaviors with 17 questions ranked on a 5-point scale, from "never" to "very often". The minimum raw summed score is 0 and the maximum score is 68. Lower scores suggest little to no opioid misuse.
Baseline vs. 4 months
Criterios de elegibilidad

Criterios de edad
Adulto, Adulto mayor
Edad mínima
18 Years
Criterios de sexo
Todos
  • Ages 18-75
  • Pain duration > 6 months
  • Must meet the minimum criteria for cognitive function using the PROMIS 2-item cognitive screener (>3)
  • Average pain score of > 3/10, with low back pain being the primary pain site
  • CLBP meeting Quebec Task Force Classification System categories I-III (from axial pain only to pain radiating beyond the knee without neurological signs). Constant radicular pain associated with sensory loss is highly treatment resistant without surgery
  • In the investigator's judgment, evidence of healthcare seeking for low back pain.
  • Must meet criteria for high negative affect at 1st study visit: at least 5 on the PHQ-4 (also called the PHQ-2 + GAD-2). Scores above this level are highly associated with having a co-morbid major depression or generalized anxiety disorder diagnosis
  • Having accessible electronic medical records from UPMC, Brigham and Women's Hospital, or Mayo Clinic, Rochester.
  • For those taking opioids (the opioid subgroup), participants must be prescribed opioids currently for at least 3 consecutive months prior to enrollment. Patients must be on opioids for a minimum of three months, taking them on a daily basis or intermittently during the week. The investigators will include those on strong opioids, such as oxycodone and weak opioids, such as tramadol.
  • Subject must agree that opioids cannot be increased during the study
  • For those taking opioids, no active substance use disorder in the past year as determined by the PI with the use of the Tobacco, Alcohol, Prescription Medications, and Other Substance Tool (TAPS) and a urine toxicology screen. The exceptions are tobacco, medical marijuana use in Pennsylvania or Minnesota, recreational or medical marijuana in the Boston site, or mild prescription opioid use disorder such as opioid misuse
  • No acute suicidality or history of major thought disorder (such as mania or psychosis). This will be assessed at study entry which will also include a review of history in EPIC/EMR
  • Must possess a mobile device or tablet that can send and receive text messages and access the internet

  • Back surgery within the past six months
  • Active worker's compensation or litigation claims
  • New pain and/or psychiatric treatments within 2 weeks of enrollment
  • Intent to add new or increase pain treatments during the study period, such as back surgery, nerve block procedures, or medications
  • Intent to add new psychiatric treatments during the first 4 months of the study
  • Any clinically unstable systemic illness that is judged to interfere with the trial
  • History of cardiac, nervous system, or respiratory disease that, in the investigator's judgment, precludes participation in the study because of a heightened potential for respiratory depression
  • Non-ambulatory status
  • Pregnancy or the intent to become pregnant during the study. Women of childbearing potential will all submit a urine sample pregnancy testing at enrollment.
  • Not fluent in English and/or not able to complete the questionnaires
Ajay Wasan, MD, Msc logoAjay Wasan, MD, Msc
  • ⚕️National Institutes of Health (NIH)
  • 🏛️National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  • Mayo Clinic logoClínica Mayo868 ensayos clínicos activos para explorar
  • 🏥Massachusetts General Hospital
Parte responsable del ensayo
Ajay Wasan, MD, Msc, Investigador-patrocinador, Professor, University of Pittsburgh
No hay datos de contacto.
3 Sitios del ensayo en 1 países

Massachusetts

BWH Pain Management Center, Chestnut Hill, Massachusetts, 02467, United States

Minnesota

Mayo Clinic, Rochester, Minnesota, 55905, United States

Pennsylvania

UPMC Pain Medicine At Centre Commons, Pittsburgh, Pennsylvania, 15206, United States